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ABSTRACT Malaria is a disease that affects nearly 40% of the global population, and chemotherapy
remains the mainstay of its control strategy. The global malaria situation is increasingly being exacerbated
by the emergence of drug resistance to most of the available antimalarials, necessitating search for novel
drugs. A recent rational approach of antimalarial drug design characterized as ‘‘covalent bitherapy’’
involves linking two molecules with individual intrinsic activity into a single agent, thus packaging dual-
activity into a single hybrid molecule. Current research in this ﬁeld seems to endorse hybrid molecules as
the next-generation antimalarial drugs. If the selective toxicity of hybrid prodrugs can be demonstrated in
vivo with good bioavailability at the target site in the parasite, it would offer various advantages including
dosage compliance, minimized toxicity, ability to design better drug combinations, and cheaper
preclinical evaluation while achieving the ultimate object of delaying or circumventing the development
of resistance. This review is focused on several hybrid molecules that have been developed, with particular
emphasis on those deemed to have high potential for development for clinical use. Drug Dev Res
71:20–32, 2010. r 2009 Wiley-Liss, Inc.
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INTRODUCTION
Chloroquine (CQ), a 4-aminoquinoline, has been
the mainstay of malarial chemotherapy for much of the
past ﬁve decades. The drug has several advantages
including limited host toxicity, ease of use, low cost, and
effective synthesis. However, the use of CQ been
eroded by development of resistance [Vangapandu
et al., 2003; Kouznetsov and Go ´mez-Barrio, 2009].
Unfortunately, most AQ drugs are structurally related,
and show cross-resistance [Foley and Tilley, 1998;
Bloland, 2001]. Currently, artemisinin-based combina-
tion therapy (ACT) is the World Health Organization
(WHO) golden standard against Plasmodium falciparum
malaria, in which the regimen uses a double- or
triple-combination therapy geared towards delay of
resistance, or circumvents it altogether [Capela et al.,
2009; Arau ´jo et al., 2009; Maude et al., 2010]. Although
no clinical resistance has been registered against
artemisinins, recent reports from south-east Asia are
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resistance against this class of drugs [Noedl et al.,
2008]. Extensive spread of drug resistance involving
classical antimalarials by P. falciparum, the most lethal
strain of human malarial pathogen, necessitates a
sustained search for promising compounds preferably
with novel chemical structures and mechanism of
action [Basco et al., 2001].
In the past two decades, only a few compounds
belonging to a new class of antimalarial drugs,
including aminoalcohols (meﬂoquine, halofantrine,
lumefantrine), sesquiterpene trioxanes (artemisinin
derivatives), and naphthoquinones (atovaquone) have
been developed for clinical usage [Basco et al., 2001].
One of the challenges of future malarial chemotherapy
is to develop compounds that are innovative with
respect to the chemical scaffold and molecular target
[Olliaro and Wells, 2009]. Many approaches to
antimalarial drug discovery currently being deployed
include optimization of therapy with available drugs
including combination therapy, developing analogs of
the existing drugs, evaluation of potent agents from
natural products especially plants, use of compounds
originally developed against other diseases, and evalua-
tion of drug-resistance reversers (chemosensitizers) as
well as new chemotherapeutic targets [Rosenthal,
2003; Kouznetsov and Go ´mez-Barrio, 2009]. Recently
through rational drug design approach, single hybrid
molecules with dual functionality and/or targets have
been developed as novel antimalarial drugs. Some of
these hybrid drugs have been demonstrated to be
potent antimalarial agents, possessing no or minimum
toxicity [Benoit-Vical et al., 2007; Cosle ´dan et al.,
2008]. However, so far none of these hybrid antimalar-
ials have reached clinical application.
In malaria drug combination therapy, the current
trend is to co-formulate two or more agents into
a single tablet, termed as multicomponent drug
(e.g., Coartem
s, lumefantrine-artemether) as opposed
to the traditional cocktail therapy, so as to improve
patient compliance [Morphy and Rankovic, 2005].
However, based on the wide interest in the hybrid
molecules as well as numerous encouraging efﬁcacy
and toxicity reports, the next generation of antimalarials
may as well be hybrid drugs as opposed to multi-
component ones. There are numerous advantages of
employing hybrid molecules over multicomponet drugs
in malaria therapy. Compared to the latter, hybrid
drugs may be less expensive since, in principle, the
risks and costs involved may not be different from
any other single entity. Another advantage is that of
the lower risk of drug–drug adverse interactions
compared to multicomponent drugs. The downside,
however, is that it is more difﬁcult to adjust the ratio
of activities at the different targets [Morphy and
Rankovic, 2005].
Hybrid molecules can be classiﬁed as:
1. Conjugates, in which the molecular frameworks,
that contain the pharmacophores for each target are
separated by a distinct linker group that is not found
in either of the individual drugs. Most conjugates
contain a metabolically stable linker [Morphy and
Rankovic, 2005].
2. Cleavage conjugates have a linker designed to be
metabolized to release the two drugs that interact
independently with each target.
3. Fused hybrid molecules have the size of the linker
decreased such that the framework of the pharma-
cophores is essentially touching.
4. Merged hybrids have their frameworks merged by
taking advantage of commonalities in the structures
of the starting compounds, which give rise to smaller
and simpler molecules [Morphy and Rankovic,
2005].
Quinine from Peruvian Cinchona trees provided
the lead for the discovery and development of synthetic
aminoquinolines, the most notable being CQ [Wang
et al., 2007; Cosle ´dan et al., 2008]. Likewise, the
discovery of artemisinin from the Chinese herb
Artemisia annua has served as a template for develop-
ment of semi-synthetic artemisinins including artesu-
nate and artemether, which are being used extensively
in ACT against drug-resistant malaria [Maude et al.,
2010]. The commercial availability of artemisinin (and
hence its semi-synthetic derivatives) is limited by the
fact that it is a natural product from Artemisia annua.
Today, no fully synthetic peroxidic antimalarial drug has
been made available for clinical application, which is
unfortunate because of limitations associated with
artemisinin semi-synthetics. The limitations include
chemical (availability, purity, and cost), bio-pharma-
ceutical (poor bioavailability and limiting pharmacoki-
netics), and treatment (non-compliance with repeated
regimens and recrudescence) issues that limit their
therapeutic potential [Vennerstrom et al., 2004; Perry
et al., 2006]. As a result, extensive research into
synthetic endoperoxide antimalarials drugs has been
undertaken in the last 15 years to produce molecules
that are structurally simpler and synthetically acces-
sible with a projected low cost of goods [Sabbani et al.,
2008]. Recently, fully synthetic peroxidic antimalarials
are being developed, in which the pharmacophore of
artemisinin is present within a 1,2,4-trioxalane, termed
ozonide, rather than a 1,2,4-trioxane heterocycle of
artemisinin [Uhlemann et al., 2007]. Synthetic 1,2,4-
trioxolane derivatives being investigated as a new class
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of synthesis, improved biopharmaceutical properties,
and excellent efﬁcacy proﬁles compared with currently
available artemisinin derivatives [Vennerstrom et al.,
2004; Creek et al., 2008]. Other synthetic cyclic
endoperoxides being explored include 1,2-dioxanes,
1,2,4-trioxanes, and 1,2,4,5-tetraoxanes, all of which
retain the critical endoperoxide bond, which confers
activity to artemisinins [Sabbani et al., 2008].
Recently, in a deliberate rational design of
antimalarials acting speciﬁcally on multiple targets,
several hybrid molecules have been developed in what
has been termed ‘‘covalent biotherapy.’’ One instance is
where a trioxane or trioxolane motif is covalently linked
to a quinoline entity, to form new modular molecules
referred to as trioxaquines or trioxolaquines, respec-
tively [Arau ´jo et al., 2009]. The quinoline nucleus has
been a chemical reference of highly active antimalarial
drugs for many decades and several effective drugs
containing this entity including CQ, meﬂoquine,
amodiaquine, and primaquine have been developed.
The trioxanes and trioxolanes contain a peroxide
bridge, which is essential for the high activity of
artemisinin and its semi-synthetics including arte-
mether, arteether, dihydroartemisinin, and artesunate.
As the trioxane or trioxolane moiety is a potential
alkylating agent after reductive activation by heme, and
the 4-aminoquioline entity easily penetrates into
infected erythrocytes and then interacts with heme,
such modular molecules are expected to combine the
dual activity of both fragments [Basco et al., 2001].
Trioxaquines are potent antimalarial drugs against both
asexual and sexual malarial stages, and their potency is
independent of CQ-sensitivity of the target parasite
[Benoit-Vical et al., 2007].
HYBRID MOLECULES WITH PROMISING CLINICAL
PROSPECTS
Fully Synthetic Peroxidic Molecules as Raw
Materials for Hybrid Molecules
Endoperoxides currently in clinical use are semi-
synthetics of the artemisinins, which include arteether,
artemether, artelinic acid, and artesunate. Although
these peroxides are highly potent with fast parasite
clearance and broad parasite stage speciﬁcity, their
major limitation is their short half-life, requiring
regular dosing, which may lead to non-compliance
and recrudescence [Gautam et al., 2009]. Therefore,
these artemisinin semi-synthetic molecules are used in
combination with long-acting antimalarial drugs in
what is termed ACT [Maude et al., 2010]. Although the
detailed mechanism of action of sesquiterpene lactone
artemisinin, which contains a peroxide bond in the
form of 1,2,4-trioxane heterocycle [Zhou et al., 2008],
remains to be elucidated, it is widely accepted that its
activity resides on the endoperoxide function. Basically,
the cleavage of the endoperoxide-bridge by monomeric
haem, which is released during parasites haemoglobin
metabolism, forms carbon-centred free radicals, lead-
ing to alkylation of haem and other parasite biomole-
cules [Meshnick et al., 1993; Wei and Sadrzadeh, 1994;
Robert and Meunier, 1998].
Since the 1980s, there have been concerted
efforts to shift from reliance on the ﬁrst-generation
artemisinin analogs, e.g., artemether and artesunate,
and fully synthetic alternatives are being explored
extensively. Although artemisinin semi-synthetics are
highly potent and exhibit little or no cross-resistance
with other antimalarials, they have poor bioavailability
and pharmacokinetic properties, and are expensive
since their availability depends on the availability of
artemisinin from Artemisia annua [Ellis et al., 2008].
Concerted efforts geared towards development of fully
synthetic alternatives, which retain the peroxide
pharmacophore, have been applied for almost two
decades although none of these fully synthetic mole-
cules has reached clinical status. Efforts of the
Vennerstrom group [Vennerstrom et al., 2004], among
the pioneers in this venture led to the development of
amine peroxides containing one peroxide bridge and
later the 1,2,4,5-tetraoxanes and most recently the
1,2,4-trioxolanes (ozonides) and the clinical candidate
OZ277 (RBx-11160) (Fig. 1). The latter is a fully
synthetic trioxolane, a potent peroxidic antimalarial
with a signiﬁcantly different molecular structure from
that of artemisinins [Vennerstrom et al., 2004; Creek
et al., 2008]. To add to the superior antimalarial activity
of the ozonide relative to conventional artemisinin
semi-synthetics, oral dosing in rat models demon-
strated a remarkable benign toxicological proﬁle and
lacked neurotoxicity due to a lack of accumulation
in the brain [Vennerstrom et al., 2004]. Ellis et al.
[2008] synthesized several 1,2,4,5-tetraoxanes that had
antiplasmodial activity against P. falciparum in the
range of 40–100nM and were more stable than
synthetic 1,2,4-trioxanes and -trioxolanes. Generally,
Fig. 1. OZ277 (RBx-11160), a fully synthetic trioxolane and a potent
peroxidic antimalarial.
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were more active than the corresponding 1,2-dioxanes
[Wang et al., 2007].
Artemisinin-Based Hybrids
Trioxaquines and Trioxolaquines
Trioxaquines are synthetic hybrid molecules
containing two covalently linked pharmacophores
(1,2,4-trioxane and an aminoquinoline), a concept
referred to as ‘‘covalent biotherapy,’’ and thus possess
a dual mode of action, namely heme alkylation with the
trioxane entity, and heme stacking with the aminoqui-
noline moeity and inhibition of haemozoin formation
[Loup et al., 2007; Cosle ´dan et al., 2008]. Trioxola-
quines are hybrid molecules similar to trioxaquines
except that they contain a trioxolane motif, namely
an ozonide, instead of a trioxane entity [Cosle ´dan
et al., 2008]. The ﬁrst series of trioxaquines were
potent against both CQ and pyrimethamine-resistant
P. falciparum strains, and Benoit-Vical and co-workers
developed the second series of trioxaquines, that were
highly potent in vitro against both CQ-sensitive and
-resistant P. falciparum isolates [Benoit-Vical et al.,
2007]. The trioxaquines had more improved antimalar-
ial activity than their individual fragments, indicating a
potential additive/synergistic effect of the hybrids
[Arau ´jo et al., 2009]. Quinoline-endoperoxide hybrids
have been developed with both semi-synthetic artemi-
sinin derivatives as well as synthetic analogs, and
possess remarkable in vitro antiplasmodial activity
[Arau ´jo et al., 2009]. Incorporation of 4-aminoquino-
line or 9-aminoacridine (a component of mepacrine)
into the ﬁnal hybrid drug enhanced drug accumulation
in the digestive vacuole of the parasite thus inducing a
greater turnover of potentially toxic-free radicals by
endoperoxide bioactivation.
The potential advantage of both sets of compound
lies in their capacity to target the parasite by two
distinct mechanisms, thereby delaying or circumvent-
ing development of resistance [Arau ´jo et al., 2009].
The synthetic peroxide hybrids (1,2,4-trioxalaquines)
were generally more potent than their semi-synthetic
(1,2,4-trioxaquines) counterparts. The most potent
1,2,4-trioxalaquine (Fig. 2) showed better in vitro
antiplasmodial activity than either artemisinin or CQ
against P. falciparum isolates [Arau ´jo et al., 2009].
Although in some instances the hybrid molecule may
lack a signiﬁcant improvement of activity relative to
the individual components of the hybrid, use of the
hybrid drug would still be advantageous in several
aspects. The derivatives may readily be converted
into water-soluble salts making them suitable for oral
or intravenous formulations. Also, when the peroxide
component of the hybrid drug is ‘‘chemically con-
sumed,’’ the residual aminoquinoline or aminoacridine
constituent can still act as an efﬁcient antimalarial,
provided it is not covalently bound to the protein
[Arau ´jo et al., 2009].
Cosle ´dan et al. [2008] reported that from
2003–2006, 120 trioxaquines and trioxalaquines were
developed and evaluated for antiplasmodial activity
in vitro against both CQ-sensitive and -resistant
P. falciparum isolates, giving IC50 values of 5–74nM.
Among the 120 compounds, 72 were evaluated for their
ability to suppress the rodent parasite in mice, and 25 of
the 72 molecules were considered for additional
evaluation for in vitro absorption, distribution, metabo-
lism, excretion, and toxicological evaluation. In the
trioxaquine PA1103/SAR116242 (Fig. 3), the second
cyclohexyl ring within the linker enhanced its metabolic
stability relative to other trioxaquines with a linear
aliphatic tether. The dual mode of action of PA1103/
SAR116242 involved heme alkylation via the reductive
activation of the trioxane entity, and heme stacking with
the aminoquinoline moiety and inhibition of haemozoin
formation [Cosle ´dan et al., 2008]. The diastereoisomers
of the trioxaquine were equipotent in their in vitro
antiplasmodial activities against both CQ-sensitive and
-resistant P. falciparum isolates (IC50 values57–24nM),
an additional gain to its potential as an antimalarial
drug candidate. Both diastereoisomers had good oral
bioavailability and were equipotent by p.o. in mice
infected with P. vinckei petteri. The compound was also
equipotent against CQ-sensitive and -resistant rodent
parasites [Cosle ´dan et al., 2008]. Humanized mice
infected with human P. falciparum 3D7 (CQ-sensitive)
and W2 (CQ-resistant) were either cured or had
signiﬁcant parasitaemia reduction when treated with
the trioxaquine p.o. [Cosle ´dan et al., 2008].
The observation that PA1103/SAR116242 was
equally effective against both CQ-sensitive and -resistant
Fig. 2. A 1,2,4-trioxolaquine, a potent hybrid antimalarial drug.
Fig. 3. PA1103/SAR116242. The trioxaquine linker’s cyclohexyl ring
enhances its metabolic stability.
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the in vitro antiplasmodial outcome. In toxicological
assays, the compound lacked mutagenic or clastogenic
activity. The two separated diastereoisomers of the
trioxaquine were equipotent in both in vitro and in vivo
antiplasmodial assays, and displayed similar proﬁles
in absorption, metabolism, and safety assays. The
remarkable activity of PA1103/SAR116242 against both
CQ-sensitive and -resistant P. falciparum strains,
together with realization of dual mode of action
(artemisinin-like and CQ-like), good bioavailability and
low toxicity makes the molecule an attractive and
promising candidate for a covalent bitherapy strategy
[Cosle ´dan et al., 2008].
Benoit-Vical et al. [2007] developed ﬁve second-
generation trioxaquines (coded DU1301, DU1302,
DU1313, DU1314, and DU2302), which they studied
to reveal diverse biological activities and structural
characteristics of this class of hybrid molecules. The in
vitro antiplasmodial activities (IC50 values) of these
compounds ranged from 4–32nM and were indepen-
dent of the CQ sensitivities of the P. falciparum isolates
tested. These activities were similar to those of
artesunate, the most potent drug of the artemisinin
family available. To test the concept of dual activity of
the molecules, the quinoline and trioxane precursors
were tested individually and in combination, and their
activities compared with that of the conjugates.
Irrespective of the P. falciparum strain used, the
trioxane entity alone had IC50 values ranging from
200–600nM, while the IC50 values of the quinoline
motif alone ranged from 120nM to 2mM. In combina-
tion in the same well, both entities had IC50 values
ranging from 40–180nM, whereas the trioxaquines’
IC50 values ranged from 4–32nM, implying that the
link between both pharmacophores of the trioxaquines
is essential for their activity. The diastereoisomers of
these trioxaquines were equipotent against CQ-sensi-
tive and -resistant strains of P. falciparum, implying that
their target is achiral. In a 4-day suppressive test with
mice infected with P.v. petteri, both DU 1301 and
artesunate at doses of less than 30-mg/kg/p.o. qd
threshold achieved a complete cure without any
recrudescence. The trioxaquine, DU 1302, was an
especially promising antimalarial agent since at a dose
of 50mg/kg/day p.o., it was curative without any
recrudescence in mice infected with the lethal strain
P. yoelii nigeriensis, whereas 100-mg/kg/day p.o.
artemisinin was required for a complete cure. DU
1302 also had gametocytocidal activity that was super-
ior to that of artesunate, suggesting that the compound
has potential to interrupt malaria transmission in a
clinical situation. Furthermore, it lacked toxicity in an
HCT cell line and in a mouse model. Synthesis of this
trioxaquine prototype was also relatively simple, adding
to its advantage as a future potent antimalarial drug
[Benoit-Vical et al., 2007].
Basco et al. [2001] demonstrated that another
trioxaquine derivative (DU-1102), was highly active
against both CQ-sensitive and -resistant clinical
P. falciparum isolates (mean IC50543nM). The
responses to DU-1102 and chloroquine were, however,
not correlated, suggesting an independent mode of
action of the trioxaquine against the parasite.
Artemisinin-Dipeptidyl Vinyl Sulfone Hybrids
Cysteine proteases of the malarial parasite are of
particular interest as therapeutic targets since they play
major roles in parasite development. P. falciparum
parasite expresses four cysteine proteases from the
papain family known as falcipains, required for
degradation of hemoglobin by erythrocytic malaria
parasites, of which falcipain-2 and falcipain-3 are the
most obvious as drug targets [Olson et al., 1999; Biot
et al., 2007; Capela et al., 2009]. Several falcipain
inhibitors including ﬂuoromethyl ketones and vinyl
sulfones inhibit parasite development in cultures by
blocking the hydrolysis of host hemoglobin, and to cure
mice infected with lethal P. vinckei infection [Olson
et al., 1999]. Capela et al. [2009] have developed a
series of endoperoxide-dipeptidyl vinyl sulfone hybrid
molecules (Fig. 4) possessing dual activity of endoper-
oxide activation and falcipain inhibition. The vinyl
sulfone moiety is covalently linked to the endoperoxide
entity via the N-terminus, using a 4-hydroxymethyl-
benzoic acid linker. The conjugate inhibited CQ-
resistance P. falciparum isolate (W2) in the range
2–5nM being more active than artemisinin and
equipotent with artelinic acid. When screened against
P. falciparum isolates with different phenotypes, FCR3
(atovaquone-resistant), 3D7 (CQ-sensitive), V1/S (CQ-
and pyrimethamine-resistant), and D6 (CQ-sensitive,
meﬂoquine-resistant), compounds 4a, 4e, and 4f
(Fig. 4) had superior activity when compared to CQ
Fig. 4. Artemisinin-dipeptidyl vinyl sulfone conjugates.
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sulfones are potent irreversible falcipain inhibitors,
and hybrids that contained Leu-hPhe core inhibited
falcipain-2 in the range 0.3–22mM. The fact that the
hybrid molecule falcipain inhibition was in the micro-
molar range implies that the endoperoxide pharmaco-
phore contributed to the bulk of activity, probably due
to poor activity of the hybrids against falcipain-2 and/or
their limited access to the food vacuole [Capela et al.,
2009]. However, this served as a proof of concept, and
future work in this regard is required to optimize the
bi-functional molecule enzyme-binding capabilities.
Recently, Jones et al. [2009] reported artemisinin-
acridine hybrids that had antitumour activity against
various cell lines. Compared to dihydroartemisinin,
these 1,2,4-trioxane-acridine hybrids had moderate
antimalarial activity. While reporting on many artemi-
sinin-based hybrids, the present discussion is in no way
exhaustive, given the interest many researchers have
shown in this ﬁeld, not just for malaria chemotherapy
but also for other diseases. There thus appear to be
unlimited possibilities in which the artemisinin phar-
macophore can be exploited in covalent bitherapy by
linking it to other drug pharmacophores.
Dual-Function Acridones
Recent developments in the design and synthesis
of aminoquinoline ring-based hybrid molecules
[Kouznetsov and Go ´mez-Barrio, 2009], especially bis-
quinolines [Foley and Tilley, 1998], have been reported.
Quinoline-Chemosensitizer Hybrid Molecules
Dual-function acridones refer to hybrid molecules
based on the aminoquinoline ring, using similar
previously described ‘‘one-drug, two-targets approach’’
as for artemisinin hybrid molecules. It is widely accepted
that the parasite heme-detoxiﬁcation process after
hemoglobin metabolism is the primary target of quino-
line drugs [Foley and Tilley, 1998]. The present
evidence indicates that CQ resistance is directly
associated with mutations in the gene encoding the
digestive vacuole (DV) membrane protein of the
P. falciparum CQ-resistance transporter (PfCRT)
[Burgess et al., 2006]. The protein is predicted to
function as an exporter of ‘‘metabolites’’ from the DV
since it is a member of the drug/metabolite transporter
superfamily [Bray et al., 2005]. Efﬂux of quinoline drugs
results in reduced drug concentration at the target but
does not alter the heme target itself [Kelly et al., 2009].
Thus, the target remains vulnerable, and the parasite is
susceptible if the drug availability to the target can be
restored. This is in contrast to drug resistance on the
basis of protein target mutation, such as those that
confer resistance against antifolates. Several compounds
referred to as resistance reversers or chemosensitizers
have been studied including verapamil and imipramine
that reverse quinoline resistance [van Schalkwyk and
Egan, 2006]. Unfortunately, the chemosensitizers have
not been embraced for clinical use due to potency and
safety concerns as well as their lack of intrinsic
antimalarial efﬁcacy. Thus, their combination with
quinolines will represent monotherapy [Kelly et al., 2009].
In an attempt to surmount these limitations,
several attempts have led to the design of novel
chimeric compounds modeled on the concept that
mutations in the parasite DV membrane protein
PfCRT lead to excessive efﬂux of CQ, and that protein
activity can be inhibited by reversal agents [Burgess
et al., 2006]. Kelly and co-workers [2009] incorporated
the acridone phramacophore of the quinolines into a
chemosensitization moiety to synthesize twelve hybrid
molecules, with T3.5 [3-chloro-6-(2-diethylamino-
ethoxy)-10-(2-diethylaminol-ethyl)-acridone] (Fig. 5)
being the most promising antimalarial drug. The
heme-targeting tricyclic group with an ionizable side
chain promotes drug accumulation in the DV while a
chemosensitization moiety at the N10-position is
provided to counteract quinoline resistance. The side-
chain attachment at the central nitrogen provides a
hydrogen bond acceptor required for a chemosensiti-
zation function, a feature that is a well-established
component of the pharmacophore for effective
chemosensitizers [Kelly et al., 2007]. T3.5 had
remarkable in vitro and in vivo (in mice) activity.
T3.5 (100mg/kg/p.o. qd) for 3 days diminished
P. berghei parasitaemia by 95% with an initial high-
dose being curative (256mg/kg/day, p.o.) with no overt
Fig. 5. A generalized chemical structure of dual-function acridone
derivatives. For compound T3.5: n,m52a n dR 1,R2,R3,R45CH2CH3.The
rigid tricyclic acridone core promotes p-p stacking for haem binding. The
side chain attachment at the central nitrogen atom provides a hydrogen
bond acceptor needed for the chemosensitization function, and in
conjunction with the side chain at position 6, facilitates accumulation in
the digestive vacuole (DV) via acid trapping. [Color ﬁgures can be viewed
in the online issue, which is available at www.interscience.wiley.com]
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interaction with several quinolines including CQ,
amodiaquine, quinine, and piperaquine against multi-
drug-resistant P. falciparum isolate, Dd2 [Kelly et al.,
2009]. The synergy between T3.5 and quinine was also
observed in vivo against patent infection with quinine-
sensitive P. yoelii. Hybrid drug uptake and accumula-
tion in the DV was successful, and that drug interacted
with heme thus interfering with hemozoin formation
[Kelly et al., 2009].
A similar multi-therapeutic approach was used by
Burgess et al. [2006] to develop another hybrid
molecule derived from the CQ skeleton and imipramine
ring (Fig. 6). Imipramine is a well-known antidepres-
sant, and is one of the better-studied PfCRT reversal
agents known. The halogen core of CQ could effectively
be linked to the imipramine moiety with no loss of
heme-binding ability to yield a hybrid molecule that had
remarkable antiplasmodial activity at low nanomolar
levels against both CQ-sensitive (D6) and -resistant
(Dd2) P. falciparum isolates. In mice, the molecule
demonstrated high oral efﬁcacy (99% suppression)
against P. chabaudi without obvious toxicity [Burgess
et al., 2006]. This approach is innovative in that if such
molecules can clinically be demonstrated to enhance
quinoline activity, then the traditional and unequalled
advantages offered by 4-aminoquinolines (e.g., CQ) can
be exploited in the ﬁght against drug-resistant malaria.
These advantages include low-cost and effective synth-
esis, limited host toxicity, short-course therapy, prophy-
lactic and antipyretic effects. Furthermore, the strategy
can be exploited to design new antimalarial chemother-
apeutics to contol malaria. Thus, the design and
synthesis of quinoline-chemosensitizers dual inhibitors
or ‘‘double drugs’’ that would potentially inhibit
hemozoin formation and another target within the
malarial parasite should further be explored.
Quinoline-Novel Target Based Hybrid Molecules
Cysteine proteases play critical roles in parasite
that include but are not limited to general catabolic
functions and protein processing [Sajid and McKerrow,
2002]. As stated earlier, the P. falciparum cysteine
protease falcipains are essential for degradation of
hemoglobin during erythrocytic parasite development.
A new class of 4-aminoquinoline-based isatin deriva-
tives (Fig. 7) was designed on the basis of a multi-
therapeutic strategy. Isatin can easily be functionalized
with the thiosemicarbazone moiety that could inhibit
P. falciparum-derived cysteine proteases [Chiyanzu
et al., 2005]. Thus, the quinoline entity could inhibit
b-haematin formation whereas the isatin group inhibits
P. falciparum cysteine proteases. Reports on the target
compounds against both CQ-sensitive and -resistant
P. falciparum strains, and against recombinant falci-
pain-2, demonstrated that the strategy is feasible. The
hybrid molecules showed good in vitro antiplasmodial
activity and inhibitory activity against falcipain-2, albeit
modest. Thus, aminoquinoline-isatin hybrid molecules
should be explored further as potential leads especially
as regards the ﬂexible ethylene linker and a thiosemi-
carbazone moiety. The ethylene linker increases the
lipophilicity of the hybrid compound, which probably
aids their passage through the parasite membranes to
reach their presumed site of action, the acidic food
vacuole [Chiyanzu et al., 2005; Kouznetsov and
Go ´mez-Barrio, 2009]. Biot et al. [2007] synthesized
chimeras of thiosemicarbazones and the new drug
candidate, ferroquine, a new 4-aminoquinoline in
which a ferrocenyl group is associated with CQ
[Barends et al., 2007]. Hybrid molecules of this type
had in vitro antiplasmodial activity against both
CQ-sensitive and -resistant P. falciparum isolates,
activity that was independent of parasite CQ-suscept-
ibility [Biot et al., 2007]. Novel hybrids of phenolic
Mannich bases linked to aminoquinoline fragment
were synthesized by Chipeleme et al. [2007] and
displayed signiﬁcant antiplasmodial activity against
P. falciparum isolate W2 (CQ-resistant) and inhibited
cysteine protease falcipain-2. However, some hybrid
Fig. 6. An aminoquinoline-imipramine hybrid molecule.
Fig. 7. A 4-aminoquinoline-based isatin derivative. [Color ﬁgures can
be viewed in the online issue, which is available at www.interscience.
wiley.com]
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falcipain-2, while some were either equipotent with
CQ, or had improved activity (up to 3 times the activity
of CQ). However, the ability of these compounds to
inhibit falcipain-2 and their antiplasmodial activity
against W2 were not correlated [Chipeleme et al.,
2007]. Davioud-Charvet et al. [2001] developed
4-anilinoquinoline antimalarials based on the role
reduced glutathione (GSH) plays in protecting
P. falciparum from oxidative damage as well as in
promoting heme detoxiﬁcation [Atamna and Ginsburg,
1997; Becker et al., 2003; Wiwanitkit, 2006]. It was
rationalized that increased GSH levels lead to in-
creased CQ-resistance, and thus controlling levels of
intracellular GSH by glutathione inhibitors could
restore the efﬁcacy of CQ and other 4-aminoquinoline
analogues [Davioud-Charvet et al., 2001; Meierjohann
et al., 2002]. Novel hybrid molecules based on
aminoquinoline structures and 1,4-naphthoquinone
ring were synthesized by esteriﬁcation of naphthoqui-
nolyl alkanoic acids with the alcohol amodiaquine
derivative in the presence of dicyclohexylcarboiimide
and a 4-(dimethylamino)pyridine [Davioud-Charvet
et al., 2001]. It was anticipated that in the parasite,
the molecule could be hydrolysed into two entities,
with each product exerting its own action [Davioud-
Charvet et al., 2001]. The compounds (Fig. 8)
displayed good in vitro antiplasmodial activity against
CQ-resistant P. falciparum isolate, FcB1R (ED505
23–56nM) and remarkable low in vitro percent
cytotoxicity against hMRC-5 cells (25–35mM). The
ether analog (Fig. 7c) affected the total glutathione
content of the parasites [Davioud-Charvet et al., 2001].
These hybrid molecules of a quinoline ring–glutathione
reductase inhibitor can serve as a model for develop-
ment of novel hybrids and need to be further explored.
Other Aminoquinoline-Based Hybrids
As it was earlier noted, the evidence from
structure-activity relationship studies reveal that 4-
aminoquinoline resistance does not involve any change
to the target of this class of drugs but involves a
compound efﬂux mechanism [Solomon et al., 2008].
Efforts are ongoing to restore 4 aminoquinoline
sensitivity. These include synthesis of short chain
analogs of 4-aminoquinolines, which are active against
CQ-resistant strains of P. falciparum. However, the
downside of the strategy is that after bioactivation the
analogs are dealkylated, which lowers their lipid
solubility. Recently, Solomon et al. [2008] have
attempted to improve the lipophilicity of 4-aminoqui-
nolines linking them with the cationic amino acids
lysine and ornithine. The conjugates displayed activity
against both CQ-sensitive and multidrug-resistant
P. falciparum isolates in vitro and P. yoelii in vivo.B i o t
et al. [2004] developed several ferrocenic quinoline
derivatives including a bis-quinoline and bisferrocene.
One of the conjugates, the bis-quinoline 7-chloro-4-[4-
(7-chloro-4-quinolyl)-7-ferrocenylmethyl-1,4,7-triazacy-
clononan-1-yl]quinoline, showed potent antimalarial
activity in vitro against the CQ-resistant P. falciparum
isolate Dd2. This relatively new strategy involved
incorportation of organometallocenic moiety of ferro-
quine, which has cytotoxic properties into CQ pharma-
cophore, which enables vectorizing the drug to the
selected target [Biot et al., 2004]. Thus, the developed
conjugate was expected to achieve vacuolar accumula-
tion through pH trapping and haematin association
conferred by 4-aminoquinoline, as well as lipophilic and
redox properties conferred by ferrocenyl moiety [Biot
et al., 2004]. This strategy underlines the potential of
organometallic drug conjugates as novel antimalarials.
The 8-aminoquinoline, primaquine, is a tissue-
schizontocidal drug that exerts its action against the
primary and secondary tissue forms of the Plasmodium
[Vangapandu et al., 2003]. Primaquine toxicity, includ-
ing inducing of hemolysis, limits its use in both
prophylactic and therapeutic application. Also, its
efﬁcacy against asexual blood stages of the malarial
parasite requires unacceptably high toxic doses, pre-
cluding its use in treatment of acute malaria as a blood
schizontocide. Vangapandu et al. [2003] developed
several ‘‘double prodrugs’’ or ‘‘pro prodrugs’’ of
8-quinolineamines so as to improve their bioefﬁcacy.
A pro prodrug is a derivative that undergoes two
independent reactions to form the parent. The im-
mediate prodrug must be a chemically reactive entity
that undergoes a chemical conversion to release the
bioactive parent drug under physiological conditions.
However, this reactive prodrug is generated only after a
biological step involving enzyme-catalyzed transforma-
tion of the chemically stable pro prodrug [Vangapandu
et al., 2003]. The Vangapandu group hypothesized that
8-quinolinamine conjugates, where antimalarial analogs
are attached to a carrier molecule (pro prodrug anchor),
may carry the drug molecule to the site of action, where
it may be released as the constituent prodrug by the
Fig. 8. Aminoquinoline-glutathione reductase inhibitor conjugate
molecules.
27 HYBRID MOLECULES AS NEXT-GENERATION ANTIMALARIALS
Drug Dev. Res.action of esterases or reductases. The prodrug may
subsequently be converted to the parent via a
spontaneous independent chemical modiﬁcation.
Many of the compounds from the pro prodrug
series demonstrated promising in vivo antiplasmodial
activity against drug-sensitive and -resistant rodent
malarial parasites strains, conﬁrming the hypothetical
assumption that 8-aminoquinolines could be converted
to biologically effective redox-sensitive and esterase-
sensitive pro prodrug analogues. The most effective pro
prodrug analog had promising activity against multi-
drug-resistant P.y. nigeriensis in mice. The fact that
‘‘double prodrugs’’ displayed in vivo activity implies
that endogenous enzymes present in the liver region
achieved bioreactive and bioesterase activation to
release the parent 8-quinolinamines [Vangapandu
et al., 2003]. Rajic ´ et al. [2009] developed primaquine
conjugates in a further attempt to surmount its
inherent toxicity and rapid biotransformation to
carboxyprimaquine, which is devoid of antimalarial
activity. Primaquine conjugates with glucosamine and
two polymers of polyaspartamide type were synthe-
sized. Some of the conjugates administered p.o. to mice
infected with P. berghei parasite reduced parasitaemia
signiﬁcantly and prolonged mouse longevity, relative to
the controls [Rajic ´ et al., 2009].
FUTURE PROSPECTS OF ‘‘COVALENT BITHERAPY’’
STRATEGY
The ‘‘Covalent bitherapy’’ strategy of drug design
may ﬁnd other future potential applications, which may
include:
1. Novel antimalarial drugs: The principle of rational
drug design of hybrid molecules has the potential to
be extrapolated to other antimalarial drugs with
different targets and/or mechanisms of action other
than the ones discussed in this review. Trioxaquines
offer better antimalarial activity than the individual
components in double combination [Benoit-Vical
et al., 2007]. This may imply that interaction of the
pharmacophores of two drugs in the single-hybrid
molecule is better than that of individual drugs in a
combination. It is also possible that hybrid mole-
cules will possess superior bioavailability and/or
different mode of action from that of individual
drugs in combination. This is especially useful in
designing drugs such as the aminoquinolines (e.g.,
CQ), where resistance is not due to an altered target
but failure to access the target. It will be interesting
to evaluate whether the principle of ‘‘covalent
bitherapy’’ can be exploited to develop modular
hybrid molecules that restore activity of other dug
class such as antifolates (e.g., sulfadoxine/pyrimetha-
mine), which become ineffective due to resistance.
2. Drug-delivery system: As the search for novel drugs
continues, more drugs with novel targets are being
developed, but many of these do not reach clinical
trials due to associated toxicity. Hybrid molecules
are essentially prodrugs that aid in improving the
efﬁcacy and reducing the toxicity and other adverse
effects of drugs by controlling their pharmacokinetic
properties [Vangapandu et al., 2003]. Although
some drugs may be toxic, their pharmacophores
may not be as toxic, and it may be possible to
develop safer drugs by covalently linking these
pharmacophores with those of other drugs into
synergistic conjugates. For instance, 5-ﬂuoroorotate
(FOA) is an active antifolate that targets thymidylate
synthase (TS) of P. falciparum [Rathod et al., 1989,
1992; Rathod and Go ´mez, 1991; Go ´mez and
Rathod, 1990; Muregi et al., 2009], but its clinical
usage is curtailed by toxicity concerns. It is
noteworthy that there is no antimalarial antifolate
in clinical use that targets TS, and all antifolate
antagonists in malarial chemotherapy only target
either dihydrofolate reductase or dihydropteroate
synthase of the parasite folate metabolic pathway
[Nzila et al., 2005; Nzila, 2006]. Thus, clinical
usefulness for FOA could be achieved by covalently
linking it to another drug, ensuring safe delivery and
selective toxicity to the malarial parasite cell, with no
toxicity to the host cell. Primaquine, an 8-amino-
quinoline, is a tissue schizontocide, which has
serious side effects. Its toxicity limits its use in both
prophylactic and therapeutic applications. It is
known to induce hemolysis especially in glucose-6-
phosphate dehydrogenase (G6PD)-deﬁcient indivi-
duals [Vangapandu et al., 2003]. As described
earlier, Vangapandu and co-workers [2003] demon-
strated that 8-quinolineamines conjugates as well as
their ‘‘double prodrugs’’ had promising in vivo
activity in mice. If these compounds, in which basic
pharmacophore is primaquine, are modiﬁed to
improve their blood schizontocide activity, they
have the potential to be used as broad-spectrum
(tissue and blood schizontocides) antimalarial
agents. Conjugation of drugs may, therefore, serve
as a useful tool to improve drug solubility and
stability, and prolong drug release, reduce doses,
dosing intervals, and drug toxicity, as well as to
achieve targetability [Rajic ´ et al., 2009].
3. Multiple(compound)-pharmacophoric hybrids: Re-
cently, a highly potent and promising ACT drug, a
chlorproguanil hydrochloride-dapsone-artesunate
(CDA, Dacart
s) combination, was developed
through collaborative work between WHO, MMV,
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development were terminated prematurely because
of toxicity concerns. Dapsone is known to induce
hemolysis in G6PD-deﬁcient individuals, who repre-
sent as much as 15% of the sub-Saharan Africa
population, where over 90% of global malaria cases
and deaths occur [Olliaro and Wells, 2009]. For the
same reason, Lapdap
s (chlorproguanil-dapsone) de-
veloped by WHO/GSK/University of Liverpool colla-
boration was withdrawn from the market. The
potential of hybrid molecules linking more than two
pharmacophores could be explored, since such
compound hybrids may increase efﬁcacy while abro-
gating the underlying toxicity. It would be interesting
to see whether a hybrid molecule linking the three
pharmacophores of CDA will circumvent toxicity.
4. Tailor-made stage-speciﬁc hybrid molecules: Cova-
lently linking pharmacophores of antimalarial drugs
that possess stage-speciﬁc action may have the
potential of interrupting malaria transmission. For
instance, drugs that target early asexual forms of
the malarial parasite can be linked with the ones
that target the late stages as well as the sexual
forms (gametocytocides). Artemisinin semi-syn-
thetics (e.g., artesunate), synthetic trioxaquines
(e.g., DU1302), as well as primaquine have remark-
able gametocytocidal activity [Pukrittayakamee
et al., 2004; Benoit-Vical et al., 2007]. Artemisinins
are also known to target early forms of the parasite,
which is one of the main advantages of these drugs
in ACT, reducing chances of development of
resistance. In theory, therefore, it is possible to
design hybrid molecules that integrate the various
pharmacophores of such drugs, which will not only
lower the parasite load effectively (thus reducing
chances of resistance development), but also
targeting sexual parasite forms can go a long way
in interrupting transmission especially in malaria-
endemic areas.
5. Elucidation of ‘‘drug mechanism of action’’ as well as
‘‘drug-resistance mechanisms’’: The molecular basis
of action of most antimalarial drugs in clinical use is
poorly characterized, much less the mechanisms
involved in their resistance. While CQ action is
thought to mainly involve interference with hemo-
globin digestion in the blood stages of the malaria
parasite life cycle [Foley and Tilley, 1998], the
mechanism of action of artemisinins is a little
controversial with various targets being reported
although it is widely accepted that its activity is
mediated via the endoperoxide function. It has been
suggested that iron generates free radicals from
artemisinins, which may lead to lipid peroxidation,
protein oxidation, alkylation, and subsequent parasite
death [Meshnick et al., 1993; Robert and Meunier,
1998]. Pandey et al. [1999] also reported that
artemisinins exert their action in a similar manner
to CQ, by interfering with the hemoglobin catabolic
pathway and inhibition of heme polymerization.
Eckstein-Ludwig et al. [2003] provided compelling
evidence that after artemisinin activation by iron, it
can inhibit P. falciparum sarco/endoplamic reticulum
Ca
21-ATPase (SERCA) ortholog (PfATP6) outside
the food vacuole. PfATPase is the only SERCA-type
Ca
21 ATPase sequence in the P. falciparum genome.
CQ-resistance has been implicated with elevated
levels of drug efﬂux mediated by PfCRT, a member
of the drug/metabolite transporter superfamily
located in the intraerythrocytic parasite DV [Bray
et al., 2005]. Although controversial, overexpression
of the ATP-dependent drug transporter, P-glycopro-
tein, has also been implicated with CQ-resistance,
and the pfmdr1 gene product, PGh-1 (a typical
member of P-glycoprotein family), is localized to the
membrane of the parasite food vacuole [Foley and
Tilley, 1998]. It may be postulated that hybrid
molecules may aid in clarifying both the mechanism
of action of drugs as well as in elucidating the
mechanisms of resistance.
CONCLUDING REMARKS
Hybrid molecules with dual functionality devel-
opment and/or multitherapeutic strategies, which
utilize new chemical entities with two (or more)
different heterocyclic skeletons (pharmacophores),
represent a valid and rational approach in design and
development of novel antimalarials. These drugs have
the potential to surmount the rapid development of
resistance, enhance patient compliance, and reduce
both the cost and the risk of drug–drug interactions.
The strategy has the potential to restore efﬁcacy of
traditional drugs such as CQ, which have been
rendered ineffective due to resistance, although the
drugs had the advantage of the following beneﬁts:
affordable, effective synthesis, limited host toxicity, and
short-course therapy. The current impetus in the
search for fully synthetic peroxidic antimalarials as
well as hybrid molecules at the laboratory level is
yielding good results, and some of the drugs are now
reaching the clinical trials stage. Fully synthetic
peroxides may surmount the limitations of semi-
synthetic artemisinins as they are superior in purity,
cost, and biopharmaceutical properties. A fully syn-
thetic peroxidic antimalarial, OZ277 (RBx-1160), is
currently in development. Its combination with piper-
aquine has been promising and Phase III clinical trials
are underway in India [Uhlemann et al., 2007; Olliaro
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trials. OZ439 is a next-generation ozonide compound,
and its Phase I trials started in April 2009. It is being
developed by the Medicines for Malaria Venture
(MMV) in collaboration with Monash University and
the University of Nebraska. Since most of the ozonides
are structurally distinct from semi-synthetic artemisi-
nins, it is expected that the problem of cross-resistance
may not arise. This will be a great advantage especially
now when some reports of artemisinin clinical toler-
ance are emerging mainly from the southeast Asia
region, e.g., along the Thai-Cambodia border, which
may herald a widespread global resistance against this
class of drugs as was experienced with CQ [Olliaro and
Wells, 2009; Noedl et al., 2008]. The trioxaquine,
PA1103/SAR116242, originally developed by Palumed
has been selected for full preclinical development as a
drug candidate via the oral route, and is being
developed with Sanoﬁ-Aventis [Cosle ´dan et al., 2008;
Olliaro and Wells, 2009]. Although malarial chemother-
apy may not be the silver bullet among the tools
available for malaria control strategy, it remains the
main arsenal against malaria since a vaccine is yet to be
found, although one is in advanced clinical trials [Bejon
et al., 2008; Maher, 2008]. It is, therefore, promising
that novel antimalarial drugs are being developed, with
some reaching clinical trials and with a high potential of
clinical application.
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